×
About 30,428 results

ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Research & Reviews  15,027 results

Motor Neuron Disease Register for England, Wales and Northern Ireland-an analysis of in...
https://doi.org/10.1080/21678421.2020.1812661
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; Opie-Martin S, Ossher L et. al.

Sep 17th, 2020 - Amyotrophic lateral sclerosis (ALS) has a reported incidence of 1-2/100,000 person-years. It is estimated that there are 5000 people with ALS in the UK at any one time; however, the true figure and geographical distribution, are unknown. In this s...

"Re-identifying yourself": a qualitative study of veteran views on implantable BCI for ...
https://doi.org/10.1080/17483107.2020.1817991
Disability and Rehabilitation. Assistive Technology; Versalovic E, Diamond M et. al.

Sep 17th, 2020 - Brain-computer interface (BCI) technology to assist with mobility and communication is an active area of research in amyotrophic lateral sclerosis (ALS). Implantable BCI offers promise for individuals with severe disease, such as locked-in syndrom...

Amyotrophic lateral sclerosis and lead: A systematic update.
https://doi.org/10.1016/j.neuro.2020.09.003
Neurotoxicology Farace C, Fenu G et. al.

Sep 17th, 2020 - Heavy metals are considered to be among the leading environmental factors that trigger amyotrophic lateral sclerosis (ALS). However, no convincing biopathological mechanism and therapeutic clinical implication of such metals in ALS pathogenesis ha...

Split hand and motor axonal hyperexcitability in spinal and bulbar muscular atrophy.
https://doi.org/10.1136/jnnp-2020-324026
Journal of Neurology, Neurosurgery, and Psychiatry; Shibuya K, Misawa S et. al.

Sep 16th, 2020 - The 'split hand' sign refers to preferential wasting of the thenar and first dorsal interosseous muscles with relatively sparing of the hypothenar muscles in amyotrophic lateral sclerosis (ALS) and both cortical and spinal/peripheral excitotoxic m...

Models of outpatient neuropalliative care for patients with amyotrophic lateral.
https://doi.org/10.1212/WNL.0000000000010831
Neurology Phillips JN, Besbris J et. al.

Sep 16th, 2020 - To describe some current models of outpatient neuropalliative care available to patients with amyotrophic lateral sclerosis at different institutions within the United States. Six neuropalliative care physicians were asked to contribute written de...

see more →

Guidelines  9 results

Aquestive Therapeutics Receives FDA Approval for Exservan (riluzole) Oral Film
http://aquestive.com/aquestive-therapeutics-receives-fda-approval-for-exservan-riluzole-oral-film/

Nov 24th, 2019 - Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that Exservan™ (riluzole) Oral Film received early-act...

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyot...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.

Jan 8th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

MDA U.S. Neuromuscular Disease Registry
https://www.mda.org/services/neuromuscular-disease-registry
Muscular Dystrophy Association (USA)

Dec 31st, 2015 - In 2013, MDA launched the U. S.

EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--rev...
https://doi.org/10.1111/j.1468-1331.2011.03501.x
European Journal of Neurology; , Andersen PM et. al.

Sep 14th, 2011 - The evidence base for the diagnosis and management of amyotrophic lateral sclerosis (ALS) is weak. To provide evidence-based or expert recommendations for the diagnosis and management of ALS based on a literature search and the consensus of an exp...

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.

Oct 13th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

see more →

Drugs  27 results see all →

Clinicaltrials.gov  15,161 results

Motor Neuron Disease Register for England, Wales and Northern Ireland-an analysis of in...
https://doi.org/10.1080/21678421.2020.1812661
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; Opie-Martin S, Ossher L et. al.

Sep 17th, 2020 - Amyotrophic lateral sclerosis (ALS) has a reported incidence of 1-2/100,000 person-years. It is estimated that there are 5000 people with ALS in the UK at any one time; however, the true figure and geographical distribution, are unknown. In this s...

"Re-identifying yourself": a qualitative study of veteran views on implantable BCI for ...
https://doi.org/10.1080/17483107.2020.1817991
Disability and Rehabilitation. Assistive Technology; Versalovic E, Diamond M et. al.

Sep 17th, 2020 - Brain-computer interface (BCI) technology to assist with mobility and communication is an active area of research in amyotrophic lateral sclerosis (ALS). Implantable BCI offers promise for individuals with severe disease, such as locked-in syndrom...

Amyotrophic lateral sclerosis and lead: A systematic update.
https://doi.org/10.1016/j.neuro.2020.09.003
Neurotoxicology Farace C, Fenu G et. al.

Sep 17th, 2020 - Heavy metals are considered to be among the leading environmental factors that trigger amyotrophic lateral sclerosis (ALS). However, no convincing biopathological mechanism and therapeutic clinical implication of such metals in ALS pathogenesis ha...

Split hand and motor axonal hyperexcitability in spinal and bulbar muscular atrophy.
https://doi.org/10.1136/jnnp-2020-324026
Journal of Neurology, Neurosurgery, and Psychiatry; Shibuya K, Misawa S et. al.

Sep 16th, 2020 - The 'split hand' sign refers to preferential wasting of the thenar and first dorsal interosseous muscles with relatively sparing of the hypothenar muscles in amyotrophic lateral sclerosis (ALS) and both cortical and spinal/peripheral excitotoxic m...

Models of outpatient neuropalliative care for patients with amyotrophic lateral.
https://doi.org/10.1212/WNL.0000000000010831
Neurology Phillips JN, Besbris J et. al.

Sep 16th, 2020 - To describe some current models of outpatient neuropalliative care available to patients with amyotrophic lateral sclerosis at different institutions within the United States. Six neuropalliative care physicians were asked to contribute written de...

see more →

News  177 results

BrainStorm to study stem cell treatment in Alzheimer's patients
https://www.reuters.com/article/us-brainstorm-cell-alzheimers-study/brainstorm-to-study-stem-cell-treatment-in-alzheimers-patients-idUSKBN23V1PO

Jun 24th, 2020 - TEL AVIV (Reuters) - BrainStorm Cell Therapeutics Inc said on Wednesday it will begin a clinical trial of its experimental stem cell treatment in patients with Alzheimer’s disease. The U.S.-Israeli company is already conducting advanced trials of ...

Amylyx drug helps slow ALS progression in mid-stage study
https://www.reuters.com/article/us-amylyx-pharma-study/amylyx-drug-helps-slow-als-progression-in-mid-stage-study-idUSKBN1YL1KH

Dec 17th, 2019 - (Reuters) - Privately held drug developer Amylyx Pharmaceuticals Inc said on Tuesday its experimental therapy to treat amyotrophic lateral sclerosis (ALS) helped slow the progression of the fatal neurological disorder in a mid-stage study. ALS, al...

Aquestive Therapeutics Receives FDA Approval for Exservan (riluzole) Oral Film
http://aquestive.com/aquestive-therapeutics-receives-fda-approval-for-exservan-riluzole-oral-film/

Nov 24th, 2019 - Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that Exservan™ (riluzole) Oral Film received early-act...

FDA approves Aquestive's ALS treatment
https://www.reuters.com/article/us-fda-aquestive/fda-approves-aquestives-als-treatment-idUSKBN1XW2AQ

Nov 22nd, 2019 - (Reuters) - The U.S. Food and Drug Administration on Friday approved bit.ly/2pIFzi5 Aquestive Therapeutics' treatment for neurological disorder amyotrophic lateral sclerosis (ALS). Shares of the company, which developed riluzole oral film (ROF) an...

Researchers identify common reasons for misdiagnosis of ALS
https://www.mdedge.com/jcomjournal/article/210441/neuromuscular-disorders/researchers-identify-common-reasons-misdiagnosis?channel=39313
Erik Greb

Oct 19th, 2019 - AUSTIN – Lack of upper motor neuron signs on examination, presence of sensory symptoms, and absence of tongue fasciculations are common causes of amyotrophic lateral sclerosis (ALS) misdiagnosis, according to an investigation presented at the annu.

see more →

Patient Education  27 results see all →